What is the optimal first-line regimen for patients with advanced HER2-positive breast cancer: A systematic review and network meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Systematic review reveals THPyr offers best progression-free survival and overall survival in HER2-positive breast cancer patients.

The THPyr regimen showed the most significant progression-free survival benefit among therapies tested.
Nineteen randomized controlled trials involving 3,887 participants contributed to the analysis outcomes.
Network meta-analysis ranked fourteen treatment regimens based on survival and response rates.
Findings suggest THPyr may be approved as the preferred first-line treatment for advanced HER2-positive breast cancer.

Wei et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark